Clinical, radiographic and molecular characterization of two unrelated families with multicentric osteolysis, nodulosis, and arthropathy.
Arthropathy
Exome sequencing
Finland
Longitudinal survey
MMP2
Nodulosis
Pakistan
Skeletal deformities
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
14 Sep 2023
14 Sep 2023
Historique:
received:
27
03
2023
accepted:
05
09
2023
medline:
18
9
2023
pubmed:
15
9
2023
entrez:
14
9
2023
Statut:
epublish
Résumé
Multicentric osteolysis nodulosis and arthropathy (MONA) is a rare autosomal recessive disorder characterized by marked progressive bone loss and joint destruction resulting in skeletal deformities. MONA is caused by MMP2 deficiency. Here we report clinical and molecular analyses of four patients in two families from Pakistan and Finland. Clinical analyses including radiography were completed and blood samples were collected. The extracted DNA was subjected to whole-exome analysis or target gene sequencing. Segregation analyses were performed in the nuclear pedigree. Pathogenicity prediction scores for the selected variants and conservation analyses of affected amino acids were observed. The phenotype in the four affected individuals was consistent with multicentric osteolysis or MONA, as the patients had multiple affected joints, osteolysis of hands and feet, immobility of knee joint and progressive bone loss. Long-term follow up of the patients revealed the progression of the disease. We found a novel MMP2 c.1336 + 2T > G homozygous splice donor variant segregating with the phenotype in the Pakistani family while a MMP2 missense variant c.1188 C > A, p.(Ser396Arg) was homozygous in both Finnish patients. In-silico analysis predicted that the splicing variant may eventually introduce a premature stop codon in MMP2. Molecular modeling for the p.(Ser396Arg) variant suggested that the change may disturb MMP2 collagen-binding region. Our findings expand the genetic spectrum of Multicentric osteolysis nodulosis and arthropathy. We also suggest that the age of onset of this disorder may vary from childhood up to late adolescence and that a significant degree of intrafamilial variability may be present.
Sections du résumé
BACKGROUND
BACKGROUND
Multicentric osteolysis nodulosis and arthropathy (MONA) is a rare autosomal recessive disorder characterized by marked progressive bone loss and joint destruction resulting in skeletal deformities. MONA is caused by MMP2 deficiency. Here we report clinical and molecular analyses of four patients in two families from Pakistan and Finland.
METHODS
METHODS
Clinical analyses including radiography were completed and blood samples were collected. The extracted DNA was subjected to whole-exome analysis or target gene sequencing. Segregation analyses were performed in the nuclear pedigree. Pathogenicity prediction scores for the selected variants and conservation analyses of affected amino acids were observed.
RESULTS
RESULTS
The phenotype in the four affected individuals was consistent with multicentric osteolysis or MONA, as the patients had multiple affected joints, osteolysis of hands and feet, immobility of knee joint and progressive bone loss. Long-term follow up of the patients revealed the progression of the disease. We found a novel MMP2 c.1336 + 2T > G homozygous splice donor variant segregating with the phenotype in the Pakistani family while a MMP2 missense variant c.1188 C > A, p.(Ser396Arg) was homozygous in both Finnish patients. In-silico analysis predicted that the splicing variant may eventually introduce a premature stop codon in MMP2. Molecular modeling for the p.(Ser396Arg) variant suggested that the change may disturb MMP2 collagen-binding region.
CONCLUSION
CONCLUSIONS
Our findings expand the genetic spectrum of Multicentric osteolysis nodulosis and arthropathy. We also suggest that the age of onset of this disorder may vary from childhood up to late adolescence and that a significant degree of intrafamilial variability may be present.
Identifiants
pubmed: 37710205
doi: 10.1186/s12891-023-06856-2
pii: 10.1186/s12891-023-06856-2
pmc: PMC10503101
doi:
Substances chimiques
Matrix Metalloproteinase 2
EC 3.4.24.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
735Subventions
Organisme : Pakistan Science Foundation
ID : PSF/Res/P-PU/Biotech (239)
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Cureus. 2021 Jul 25;13(7):e16615
pubmed: 34466312
J Hum Genet. 2010 Nov;55(11):764-6
pubmed: 20720557
Hum Genet. 2003 May;112(5-6):441-56
pubmed: 12627295
J Bone Miner Res. 2007 Feb;22(2):329-33
pubmed: 17059372
Eur J Pediatr. 2013 Dec;172(12):1657-63
pubmed: 23900523
Science. 1999 Jun 4;284(5420):1667-70
pubmed: 10356396
Clin Genet. 2006 Mar;69(3):271-6
pubmed: 16542393
J Hum Genet. 2014 Nov;59(11):631-7
pubmed: 25273674
Eur J Hum Genet. 2009 May;17(5):565-72
pubmed: 18985071
J Comput Biol. 1997 Fall;4(3):311-23
pubmed: 9278062
Nat Genet. 2001 Jul;28(3):261-5
pubmed: 11431697
Cell Biosci. 2017 May 19;7:26
pubmed: 28533900
Sci Rep. 2016 Sep 30;6:34017
pubmed: 27687687
Front Physiol. 2020 Sep 25;11:568718
pubmed: 33101055
Clin Genet. 2005 Mar;67(3):261-6
pubmed: 15691365
Genet Couns. 2012;23(2):175-84
pubmed: 22876575
Am J Hum Genet. 2012 Sep 7;91(3):572-6
pubmed: 22922033
Clin Dysmorphol. 2007 Apr;16(2):95-100
pubmed: 17351352
Am J Roentgenol Radium Ther Nucl Med. 1969 May;106(1):121-8
pubmed: 4238825
Dis Model Mech. 2022 Oct 1;15(10):
pubmed: 36285626
Mol Genet Genomic Med. 2019 Aug;7(8):e802
pubmed: 31268248
Am J Med Genet A. 2016 Feb;170A(2):410-417
pubmed: 26601801
J Clin Res Pediatr Endocrinol. 2014;6(1):40-6
pubmed: 24637309
Eur J Pediatr. 2010 Mar;169(3):363-7
pubmed: 19653001
Ann Rheum Dis. 2016 Jan;75(1):e1
pubmed: 26420579
Sci Rep. 2019 Mar 20;9(1):4905
pubmed: 30894640
Semin Cell Dev Biol. 2008 Feb;19(1):34-41
pubmed: 17707664
Bone Rep. 2021 Jul 10;15:101106
pubmed: 34307793